Cargando…

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation

Group 2 innate lymphoid cells (ILC2) increase in frequency in eczema and allergic asthma patients, and thus represent a new therapeutic target cell for type-2 immune-mediated disease. The bromodomain and extra-terminal (BET) protein family of epigenetic regulators are known to support the expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kerscher, Bernhard, Barlow, Jillian L., Rana, Batika M., Jolin, Helen E., Gogoi, Mayuri, Bartholomew, Michelle A., Jhamb, Deepali, Pandey, Ashutosh, Tough, David F., van Oosterhout, Antoon J. M., McKenzie, Andrew N. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465521/ https://www.ncbi.nlm.nih.gov/pubmed/31024538 http://dx.doi.org/10.3389/fimmu.2019.00678

Ejemplares similares

Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
por: Kang, Sun Kyoung, et al.
Publicado: (2020)

The bromodomain inhibitor IBET-151 attenuates vismodegib-resistant esophageal adenocarcinoma growth through reduction of GLI signaling
por: Alvarez-Trotta, Annamil, et al.
Publicado: (2020)

The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats
por: Piquereau, Jérôme, et al.
Publicado: (2019)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

Bromodomain inhibitor I‐BET151 suppresses immune responses during fungal–immune interaction
por: Domínguez‐Andrés, Jorge, et al.
Publicado: (2019)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

BET bromodomain proteins are required for glioblastoma cell proliferation
por: Pastori, Chiara, et al.
Publicado: (2014)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
por: Ostriker, Allison C., et al.
Publicado: (2015)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Mietton, Flore, et al.
Publicado: (2017)

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
por: Lambert, Jean-Philippe, et al.
Publicado: (2019)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
por: Mao, Wendy, et al.
Publicado: (2019)

Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022)

BET bromodomain inhibition suppresses T(H)17-mediated pathology
por: Mele, Deanna A., et al.
Publicado: (2013)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
por: Dutra, Luiz Antonio, et al.
Publicado: (2017)

BET bromodomain proteins regulate enhancer function during adipogenesis
por: Brown, Jonathan D., et al.
Publicado: (2018)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries
por: Wang, Bowen, et al.
Publicado: (2015)

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer
por: Shu, Shaokun, et al.
Publicado: (2016)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
por: Filippakopoulos, Panagis, et al.
Publicado: (2012)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability
por: Lori, Laura, et al.
Publicado: (2016)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
por: Groves, Ian J., et al.
Publicado: (2020)

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart
por: Piquereau, Jérôme, et al.
Publicado: (2019)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Bi-directional regulation of cartilage metabolism by inhibiting BET proteins—analysis of the effect of I-BET151 on human chondrocytes and murine joints
por: Dai, Jin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vbq2bi8thpbnmrfdc5djsvoq67